Global Breast Cancer Academy

Sharing Best Practices to Optimize Patient Care in Europe

Register Now

Overview

In recent years, rapid advancements in treatment options for HR+ mBC have transformed care paradigms. Innovations in endocrine therapy, the development of targeted agents, and improved understanding of biomarkers and resistance mechanisms have opened new paths for tailored patient care. To address the evolving complexity in HR+ mBC treatment, Aptitude Health established the Global Breast Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.

Register Now

Date and Location

26 November 2024; Virtual Meeting

Meeting Content

View the slides and watch the video of the event.

View Slides Watch Video

Chair

Nadia Harbeck

Nadia Harbeck, MD, PhD

Ludwig-Maximilian University of Munich, Germany

Faculty

Antonio Llombart

Antonio Llombart, MD, PhD

University Hospital Arnau de Vilanova, Valencia, Spain

Joseph Gligorov

Joseph Gligorov, MD, PhD

Sorbonne University and Tenon Hospital (AP-HP), Paris, France

Agenda

This interactive virtual meeting with global experts will focus on the treatment of patients with HR+ breast cancer in Europe.

  • Follow presentations and engage with the faculty in case-based panel discussions on optimal treatment and patient access, and regional challenges across Europe

Download Agenda (PDF)

 

Time Topic Speaker
16.30 – 16.40 Welcome and meeting overview; introduction to the voting system Nadia Harbeck
Advancing Treatment Strategies in HR+ mBC: From Endocrine Therapy Foundations to Novel Targeted Options
16.40 – 17.00

Endocrine therapy of HR+ mBC – where to start and where to go (15-min presentation + 5-min Q&A)

  • Discuss the selection of patients who are most suitable for ET vs ET + CDK4/6 inhibitor as a first-line treatment
  • Explore the importance of ESR1 mutations and the role of oral SERDs (eg, elacestrant) in the treatment landscape
 Nadia Harbeck
17.00 – 17.20

Beyond endocrine therapy in HR+ mBC (15-min presentation + 5-min Q&A)

  • Discuss the role of biomarkers, molecular profiling, and resistance mechanisms in guiding treatment decisions
  • Explore the role of targeted therapies such as PI3K inhibitors (eg, alpelisib), mTOR inhibitors (eg, everolimus), AKT inhibitors (eg, capivasertib), and PARP inhibitors (eg, olaparib) after failure of ET
 Joseph Gligorov
17.20 – 17.40

Treatment options for high-risk and endocrine-resistant HR+ mBC (15-min presentation + 5-min Q&A)

  • Define the criteria and characteristics of high risk in HR+ mBC
  • Discuss the role of chemotherapy for patients with high-risk or endocrine-resistant disease
  • Discuss treatment options for HR+, HER2+ mBC
  • Review the emerging role of ADCs as a treatment option for patients who have exhausted ET options
 Antonio Llombart
17.40 – 17.50 Break  
How Does HER2+ mBC Treatment Look Today and Tomorrow?
17.50 – 18.20 Panel discussion: What is the optimal sequencing strategy for HR+, HER2– mBC? Nadia Harbeck and all faculty
18.20 – 18.35

How bright is the future of HR+, HER2– mBC? Ongoing and planned clinical trials (10-min presentation + 5-min Q&A)

  • Highlight ongoing clinical trials and novel therapeutic strategies for HR+ mBC
 Joseph Gligorov
18.35 – 19.20

BC case-based panel discussion

  • Case 1: HR+, HER2– mBC – what should be the 1L therapy after progression on adjuvant therapy with AI + CDK4/6 inhibitor?
    • (10-min presentation + 5-min discussion) – TBC
  • Case 2: HR+, HER2– mBC – 2L therapy after early progression in metastatic disease
    • (10-min presentation + 5-min discussion) – TBC
  • Case 3: HR+, HER2– mBC – 2L therapy after long exposure to ET ± CDK4/6 inhibitor
    • (10-min presentation + 5-min discussion) – TBC
 Nadia Harbeck and all faculty
19.20 – 19.30 Session close Nadia Harbeck

Register Now